



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2000 / OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
Commissioner for Patents
BOX RCE
Washington, DC 20231

Application No.	09/782,015
Filing Date	February 12, 2001
First Named Inventor	Edmund Y.M. Chein
Group Art Unit	1653
Examiner Name	Anish Gupta
Attorney Docket Number	115P002D

RECEIVED
OCT 15 2002

TECH CENTER 1600/2900

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR § 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 C.F.R. § 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. ☐ Other _____
- b. ☒ Enclosed
- i. ☐ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other Preliminary Amendment

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. ☐ Other _____

3. **Fees** The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 02-2666.
- i. ☒ RCE fee required under 37 C.F.R. § 1.17(e) 10/15/2002 AMUNDAF1 00000028 09782015
- ii. ☒ Extension of time fee (37 C.F.R. § 1.136 and 1.17) 01 FC:279 **370.00 OP**
- iii. ☐ Other: (\$0.00)
- b. ☒ Check in the amount of \$570.00 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	William E. Hickman	Registration No. (Attorney/Agent)	46,771
Signature		Date	October 3, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile under 37 CFR §1.8 on:

October 3, 2002

Name (Print/Type)	Nadya Gordon	Date	October 3, 2002
Signature			

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box RCE, Washington, DC 20231.



#115/115
10-17-02

Attorney's Docket No. 000115P002D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Edmund Y.C. Chein

Serial No.: 09/782,015

Filed: February 12, 2001

For: A METHOD OF HORMONE
TREATMENT FOR PATIENTS WITH
SYMPTOMS CONSISTENT WITH
MULTIPLE SCLEROSIS

Examiner: Gupta, Anish

Art Unit: 1653

RECEIVED

OCT 15 2002

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Box RCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination of the application filed herewith, Applicant respectfully requests entry of the amendment set forth below and consideration of the remarks which follow.

IN THE CLAIMS

Please amend Claims 10 and 14 as follows:

10. (Amended) A kit for treating symptoms associated with multiple sclerosis comprising:

human growth hormone; and

at least one of the supplemental hormones selected from the group consisting of sex hormone, melatonin, hormone, adrenal hormone, thyroid hormone, and thymus hormone,

wherein the human growth hormone and the at least one of the supplemental hormones is present in an effective amount and in an administerable form for establishing a regimen for replenishment of the human growth hormone and the at least one supplemental hormone within a body to physiological levels.

E'
20
FI